Success of Ceva’s participation in VIV MEA Abu Dhabi 5-7 February 2018

Ceva had the opportunity to launch the new vaccines Cevac New Flu H9 K and Cevac Flu H9 K during their participation at VIV MEA 2018

Ceva was present at VIV Middle East Africa 2018, which was an opportunity to launch our new vaccines Cevac New Flu H9 K and Cevac Flu H9 K to control Avian Influenza H9N2 infections in Near East, Gulf and North Africa.

Ceva Booth was displayed at the entrance of the Animal Health Hall presenting  the two sides of our innovative activities in the area. Ruminant section with our range of antibiotics (Cevolution) and our hormones range for reproduction (Reprodaction). 

The Main axes of our action in poultry production were highlighted with hatchery equipment as EggInject and Dovac and strategic vaccines as Vectormune ND , Cevac Ibird , Ceva Flu H9 K . 

In Addition , a Ceva Symposium was organized within the VIV Exhibition about the management of Poultry respiratory diseases :" How to control the mutual conspiracy of respiratory viruses?"

The symposium held in front of more than 150 attendees described the impact of Avian influenza H9N2, with Pr Vilmos; the management of Infectious Bronchitis, with Pr. M. Ceccinato and the economic consequences of Newcastle infections, with Ms. F. Gungor. The main lines of Ceva strategy were summarized by P Paulet and B Le Tallec when the involvement of Ceva in the quality of vaccination was pin-pointed by Christo Visagie and the certification of CHICK program by Bureau Veritas.

The Symposium was followed by a Gala Dinner on the
beach in front of the Grand Mosque of Abu Dhabi, gathering 200 people, customers and Ceva teams from 9 different countries:
Turkey, Iran,Lebanon, Jordan, Bahrain,Egypt,Saudi, Emirates and Oman.

Back to top